Previous 10 | Next 10 |
Cellectar Biosciences ( CLRB -25.4% ) obliterates yesterday's 24% spike with its $10M direct stock offering to institutional investors. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Virtusa (NASDAQ: VRTU ) -24% on Q4 earnings . More news on: Virtusa Corporation, Cellectar Biosciences, Inc., EDAP TMS S.A., Stocks on the move, Read more ...
FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive a...
May 16, 2019 Palm Beach, FL –May 16, 2019 – The initial diagnosis and the 2 nd opinions all show that the global medical device markets are projected to have a very healthy revenue prognosis through 2014. In the 2018 edition of the EvaluateMedTech® ...
CLRB stock has been on a tear for the better part of the early hours of trading in Wednesday’s session after Cellectar Biosciences Inc (NASDAQ:CLRB) announced major positive news related to one of its flagship drugs. The drug in question is CLR131 and once the initial results of ...
Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...
Thinly traded nano cap Cellectar Biosciences ( CLRB +30.7% ) is up on a robust 32x surge in volume in reaction to preliminary data from Cohort 6 in its Phase 1 study of CLR 131 in patients with relapsed/refractory multiple myeloma. More news on: Cellectar Biosciences, Inc., Healthcare ...
Appliance Recycling Centers of America (NASDAQ: ARCI ) +19% on Q1 earnings . More news on: Appliance Recycling Centers of America, Inc., PDS Biotechnology Corporation, The Container Store Group, Inc., Stocks on the move, Read more ...
Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to be safe and well tolerated and recommends study continue to Cohort 7 FLORHAM PARK, N.J., May 15, 2019 (GLOBE NEWSWIRE) -...
Gainers: Cellectar Biosciences (NASDAQ: CLRB ) +7% . More news on: Cellectar Biosciences, Inc., INSYS Therapeutics, Inc., Soliton, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
2024-03-28 09:15:05 ET Oppenheimer analyst issues OUTPERFORM recommendation for CLRB on March 28, 2024 07:33AM ET. The previous analyst recommendation was Outperform. CLRB was trading at $3.635 at issue of the analyst recommendation. Historical Analyst Recommendations ...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ende...